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ences in survival could be identiﬁed apart from the general ﬁnding that 
survivorship decreased as the number of positive stations increased.
In order to reconcile the Naruke and MD-ATS lymph node maps and 
permit analyses of cases with N1 and especially N2 disease to include 
larger number of patients, lymph node stations were grouped together 
into anatomical “zones”. Lymph nodes at levels 1-4 were grouped to-
gether into the “upper zone”, levels 5 and 6 into the “AP zone”, level 7 
into the “subcarinal zone”, levels 8 and 9 into the “lower zone”, levels 
10 and 11 into the “hilar zone”, and levels 12-14 into the “peripheral 
zone”. The appropriateness of grouping lymph node stations into 
“zones” was suggested by exploratory analyses that failed to identify 
signiﬁcant differences in survival in relationship to disease in all of the 
various N1 and N2 lymph node stations in data submitted from Japan, 
or from non-Japanese groups, or both. Signiﬁcant differences in sur-
vival for patients with lymph node metastases conﬁned to a single zone 
were only seen for cases of right-sided tumors with upper or subcarinal 
zone disease compared to peripheral zone metastases. No differences 
in survival were identiﬁed among patients who had single zone N2 
disease. AP zone disease in the absence of N1 metastases was associ-
ated with a better survival in patients with left upper tumors, but similar 
differences in survival were not identiﬁed for right upper lobe tumors 
with right paratracheal nodal metastases.
The potential impact of the number of involved lymph node zones 
on survival was then examined. Three groups were found to have 
signiﬁcantly different survivals: patients who had N1 single zone 
disease, those who had either multiple N1 or single N2 zone metastases 
and those who had multiple N2 lymph node zones involved. These 
prognostically distinct groups suggested that it might be appropriate to 
subdivide the current N staging descriptors into N1a (single N1 zone), 
N1b (multiple N1 zones), N2a (single N2 zones), and N2b (multiple 
N2 zones). In order to determine whether such a revision to the staging 
system should be considered, these additional N categories were ana-
lyzed in conjunction with each T stage category (e.g. T1N1a, T1N1b, 
T1N2a, T1N2b, etc.) rather than across all T stages as was done for all 
of the preceding analyses. However, the number of patients available in 
each of these subsets was too small to yield statistically valid analyses. 
Therefore, on the basis of the available data, we cannot recommend 
altering the current N stage descriptors.
In summary, analyses of clinical and pathological N staging in the 
IASLC database support the continued use of the current N descriptors 
in the lung cancer database. Additional analyses suggest that consolida-
tion of multiple lymph node stations into “zones” and stratiﬁcation of 
patients into 3 groups according to the extent of nodal disease may be 
appropriate and warrant inclusion in future studies.
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Purpose: To analyse all non-lymphatic metastatic components (T4 and 
M1) of the current TNM system of lung cancer with the objective of 
providing suggestions for the next edition of the TNM classiﬁcation for 
lung cancer.
Material and Methods: Data on 100,809 patients were submitted to 
the International Association for the Study of Lung Cancer Interna-
tional Database. 5,592 selected T4M0 and M1 patients fulﬁlled the in-
clusion criteria for the analysis. Speciﬁc categories of clinically staged 
T4 (lesions not continuous with the primary tumor) and M1 cases were 
compared with respect to overall survival using Kaplan-Meier survival 
estimates and comparisons via Cox regression analysis. Relevant ﬁnd-
ings were internally validated by geographic area and type of database, 
and externally validated by the North-American Surveillance, Epidemi-
ology and End Results Registries. 
Results: Median survival for cT4M0 with malignant pleural effusion 
was signiﬁcantly worse than that of other cT4M0 patients (8 months vs. 
13 months) and was more comparable to M1 cases with metastases to 
the lung only (10 months). M1 cases with metastases outside the lung/
pleura had a signiﬁcantly poorer prognosis than those with metastases 
conﬁned to the lung, with a median survival of 6 months.
Conclusions: Revisions to the TNM classiﬁcation system for lung 
cancer should include grouping cases with malignant pleural effusions 
and cases with nodules in the contralateral lung in the M1a category, 
and cases with distant metastases should be designated M1b. In addi-
tion, cases with nodule(s) in the ipsilateral lung (non-primary lobe), 
currently staged M1, should be reclassiﬁed as T4M0, in accordance 
with the recommendations of T descriptor sub-committee of the IASLC 
International Staging committee.
E05-05 IASLC Staging Project, Mon, Sept 3, 16:00 – 17:30
IASLC staging project: prognostic factors
Sculier, Jean-paul 
Institut Jules Bordet (ULB), Brussels, Belgium
Potential a priori useful prognostic variables for survival of patients 
presenting with lung cancer, as determined according to the series anal-
yses reported in the literature, include in addition to the TNM stage:
• Tumour characteristics : localization of metastatic sites : brain, liver, 
adrenals, bone, lung; number of metastatic sites; pleural effusion; 
type of lesions (assessable, measurable); tumour size and volume; 
histology : non-small cell lung cancer (NSCLC) or small cell lung 
cancer (SCLC); squamous cell carcinoma versus adenocarcinoma 
versus large cell carcinoma ...; neuroendocrine tumours; tumour 
differentiation and grade ; lymphatic and blood vessel invasion; 
symptoms; ﬂuorodeoxyglucose positron emission tomography 
(FDG-PET) scan
• Patients characteristics : age; sex; performance status (PS); weight 
loss; smoking history; race; comorbidities (Charslon’s index, 
Colinet’s simpliﬁed comorbidity score)
• Laboratory parameters : serum bilirubin; serum calcium ; serum 
sodium ; serum creatinine; haemoglobinemia; leucocytosis; neutro-
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philia; platelets; serum alkaline phosphatases; sGOT; sGPT; serum 
albumin; serum CEA; serum LDH; serum NSE; serum CYFRA
• Tumour biology: p53 ; Bcl-2 ; microvessel density ; VEGF; EGFR; 
c-erbB-2; Ki-67; Ras ; COX2...
The International Association for the Study of Lung Cancer (IASLC) 
staging project has allowed obtaining a huge data basis, making pos-
sible prognostic factors analyses for survival with a strong power. An 
ad hoc subcommittee to perform the analysis was created with the 
participation of Kari Chansky, John Crowley, Peter Goldstraw, Jan van 
Meerbeeck and Jean-Paul Sculier (chairperson). Due to the retrospec-
tive data collection, the data basis is heterogeneous with a lot of miss-
ing data and multiple potential prognostic variables are not present. 
For NSCLC, the analyses focused on the 12,428 stage I-IV cases for 
which we had clinical staging with the necessary descriptors and good 
data for age, sex, performance status, and histological cell type. A 
smaller subset of the advanced stage cases also contained good data 
for the following laboratory values: calcium, serum albumin, serum 
sodium, haemoglobin, and white blood cell count.
Our ﬁrst objective was to determine how best to model age, perfor-
mance status (P.S.), sex, histological cell type, and IASLC stage (i.e. 
the new staging system proposed by the IASLC), using the full set of 
cases. All those variables were found signiﬁcant prognostic factors in 
univariate analyses. Based on these results, we obtained, with a Cox 
regression model, the output of p-values and hazard ratios, shown in 
the table.
Variable p HR
Age (continuous) <.0001 1.01
Male <.0001 1.20
PS 1 <.0001 1.38
PS 2 <.0001 1.32
PS 3/4 <.0001 3.77
Squamous histology (vs. others) 0.1841 1.12
Stage II (vs. I) <.0001 1.86
Stage IIIA (vs. I) <.0001 2.85
Stage IIIB/IV (vs. I) <.0001 5.17
We also looked at global signiﬁcance tests for squamous histology 
+ squamous X stage interaction terms (P=.0048) and for the sex X 
squamous cell type interaction term (P=.012). All terms seem to be 
necessary for the model. The largest effect for squamous histology is in 
the stage I females.
Concerning laboratory data, we restricted our analyses to the IASLC 
stage IV cases. For each laboratory parameter, we used the commonly 
accepted normal range to our data. We found that the upper or lower 
limits (depending on which was relevant for a particular laboratory 
variable) provided very optimal cut-points in our database. So we 
modelled the laboratory variables using these cut-points, in conjunction 
with an ordered performance status variable, age (75 year cut-point) and 
sex, having determined that histology was not important in advanced 
NSCLC. The number of patients respectively assessable for calcium, 
serum albumin, serum sodium, haemoglobin, and white blood cell count 
were 1318, 1889, 1719, 1566 and 2128. Each of the ﬁve laboratory vari-
ables were found to be signiﬁcant prognostic factors for survival. 
Further analyses are ongoing, including those about SCLC and histo-
logical subtypes.
As there were no information available in the IASLC retrospective data 
basis for the potential prognostic role of biological molecular markers 
and of FDG-PET, it was decided to conduct, in collaboration with the 
ELCWP (European Lung Cancer Working Party), evidence medicine-
based literature reviews about those factors. 
There are more than 5,000 published original articles on tissue molecu-
lar biological prognostic factors in lung cancer, with a very variable 
methodological quality. We decided to restrict our review to published 
meta-analyses and identiﬁed as potential good prognostic variable : bcl-
2 (Martin et al,) and as poor prognostic variables : TTF1 (Berghmans 
et al), Cox2 (Mascaux et al), EGFR (Nakamura et al, Meert et al), ras 
(Mascaux et al, Huncharek et al), Ki67 (Martin et al), HER2 (Meert 
et al, Nakamura et al), VEGF (Delmotte et al), microvascular density 
(Meert et al), p53 (Steels et al, Mitsudomi et al, Huncharek et al), aneu-
ploidy (Choma et al). The prognostic value of those molecular markers 
for survival has been determined by univariate analyses, the only way 
to proceed with literature-based meta-analyses. We recommend to 
determine their independent role as prognostic factors by multivariate 
analyses taking into consideration the classical factors such as stage, 
sex, PS, age and some routine biological tests. This approach should be 
included in the future prospective study of the IASLC staging project.
The number of studies published on the prognostic value of the primary 
tumour SUV max (standardized uptake value) measured on FDG-PET 
for survival in NSCLC is much more limited. In the systematic review 
conducted by the ELCWP for the IASLC Staging Project (Berghmans, 
Paesmans, Dusart et al), 14 studies were identiﬁed, with 11 eligible 
for a literature-based meta-analysis including NSCLC only. They were 
published between 1998 and 2006. Numbers of patients ranged from 38 
to 162 (total : 1108); 9 studies identiﬁed a high SUV as a poor prognos-
tic factor for survival and 2 concluded to a non signiﬁcant effect. The 
meta-analysis revealed is that SUV max measured on primary tumour 
was a highly signiﬁcant poor prognostic factor for survival (HR : 2.13; 
95% conﬁdence interval : 1.54-2.95). The next step is to conﬁrm these 
results in a meta-analysis based on individual patients data allowing 
performing multivariate analysis taking into account well known prog-
nostic factors. We have already recommended to consider SUV max in 
the future prospective study of the IASLC staging project.
In conclusion, the signiﬁcant useful independent prognostic factors 
for survival identiﬁed by the IASLC staging project in patients with 
NSCLC are stage, sex, age and performance status. Further analyses 
are ongoing concerning some potentially prognostic routine laboratory 
variables : calcium, serum albumin, serum sodium, haemoglobin, and 
white blood cell count. Literature reviews based on meta-analyses have 
identiﬁed some possible prognostic markers such as bcl-2, TTF1, Cox2, 
EGFR, ras, Ki67, HER2, VEGF, microvascular density, p53, aneu-
ploidy. A meta-analysis based on the literature suggests that the primary 
tumour SUV max measured on FDG-PET is a highly signiﬁcant poor 
prognostic factor for survival in NSCLC. 
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